Payment overview · 2025
General Payments
$319.66
7 reported records · 5 companies
Healthcare provider profile · identity verified
Ami Bhatt, M.D
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · MELBOURNE, FL · NPI 1124373212
Verified facts
What the public records show
CMS Open Payments records show Ami Bhatt, M.D received $319.66 in general payments during 2025 across 7 reported records.
Phathom Pharmaceuticals, Inc. accounted for 55.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $178.35 | 55.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.01 | 13.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.30 | 12.6% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $33.77 | 10.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.23 | 7.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $319.66 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $178.35 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.01 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $42.01 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.30 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.30 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $33.77 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 373 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 298 | 100 |
| Losartan Potassium | Losartan Potassium | 256 | 82 |
| Lisinopril | Lisinopril | 233 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 213 | 67 |
| Metformin Hcl | Metformin Hcl | 170 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 52 |
| Simvastatin | Simvastatin | 154 | 47 |
| Alprazolam | Alprazolam | 142 | 48 |
| Omeprazole | Omeprazole | 140 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 40 |
| Gabapentin | Gabapentin | 106 | 31 |
| Trazodone Hcl | Trazodone Hcl | 93 | 29 |
| Montelukast Sodium | Montelukast Sodium | 89 | 32 |
| Ozempic | Semaglutide | 82 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 72 | 19 |
| Tramadol Hcl | Tramadol Hcl | 72 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 17 |
| Ezetimibe | Ezetimibe | 67 | 24 |
| Meloxicam | Meloxicam | 64 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 20 |
| Bupropion Xl | Bupropion Hcl | 61 | 19 |
| Synthroid | Levothyroxine Sodium | 56 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 17 |
| Sertraline Hcl | Sertraline Hcl | 48 | 16 |
| Furosemide | Furosemide | 47 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 46 | 16 |
| Eliquis | Apixaban | 45 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 23 |
| Allopurinol | Allopurinol | 44 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 24 |
| Atenolol | Atenolol | 43 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 13 |
| Potassium Chloride | Potassium Chloride | 40 | 19 |
| Fenofibrate | Fenofibrate | 39 | 13 |
| Lovastatin | Lovastatin | 39 | suppressed |
| Glipizide | Glipizide | 34 | 12 |
| Lorazepam | Lorazepam | 34 | suppressed |
| Famotidine | Famotidine | 33 | 13 |
| Carvedilol | Carvedilol | 32 | 13 |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 18 |
| Nifedipine Er | Nifedipine | 30 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 11 |
| Valsartan | Valsartan | 27 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 12 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Diazepam | Diazepam | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Topiramate | Topiramate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $319.66 · 7 records | Phathom Pharmaceuticals, Inc. | Cologuard Collection Kit, NURTEC ODT, QULIPTA, UBRELVY, VOQUEZNA, WATCHMAN FLX, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error